IGFBP3 and colorectal carcinoma: These findings may help provide a better understanding of the mechanisms of HOXD10 and its interacting targets, miR-7 and IGFBP3, in cancer progression and chemoresistance in CRC, suggesting that HOXD10 may serve as an important potential therapeutic target in this disease.